Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | qPCR etc. |
| Sample | Hela cell line |
| Expression Pattern | down-regulated |
| Function Description | The lncRNA MEG3 had effects to supress cervical cancer by regulation PI3K/AKT/Bcl-2/Bax/ P21 and PI3K/AKT/MMP-2/9 signaling pathway. |
| Pubmed ID | 28787698 |
| Year | 2017 |
| Title | LncRNA MEG3 has anti-activity effects of cervical cancer |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for cervical cancer | OMIM COSMIC |